Psychedelics Archives - Spark Newswire

2 minute read

Red Light Holland, With $12M Cash Balance & Revenue Up 33%, Remains ‘Confident’ In Business Strategy

November 29, 6:04 PM

Canada-based all-mushroom producer Red Light Holland Corp. (OTCQB: TRUFF) filed its quarterly financial statements and management discussion and analysis for the three and six months ended Sept. 30, 2023. Numbers show:

TRUFF

2 minute read

Seelos Therapeutics’ $5.55M Public Offering As Stock Drop 35%

By Lara Goldstein

November 29, 4:37 PM

Psychedelics biotech Seelos Therapeutics (NASDAQ: SEEL) announced the pricing of a new underwritten public offering for an estimated $5.5 million in gross proceeds. The offering is expected to close on or about Dec. 1, 2023.

SEEL

2 minute read

Irwin Naturals’ Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses

By Nina Zdinjak

November 28, 9:50 AM

Irwin Naturals Inc.

CSE:IWIN

2 minute read

Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans

By Lara Goldstein

November 27, 3:48 PM

A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans.

SEEL

3 minute read

Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More

By Lara Goldstein

November 24, 10:44 AM

GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan

ATAI

2 minute read

Clearmind Medicine’s Reverse Stock Split And Nasdaq Delisting Notice

By Lara Goldstein

November 21, 3:25 PM

Clearmind Medicine Inc. (NASDAQ: CMND) is set to conduct a 1-for-30 reverse share split of its issued and outstanding ordin

CMND

2 minute read

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

By Lara Goldstein

November 15, 5:20 PM

The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life Sciences (OTCMKTS: AWKNF) for Severe Alcohol Use Disorder (SAUD).

AWKNF

3 minute read

Cybin Reports Access To $101M To Sustain Deuterated Psychedelics Programs, Q2 Numbers & 2024 Goals

By Lara Goldstein

November 15, 4:38 PM

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023.

CYBN

3 minute read

GH Research: Steady Expenses And $229M Cash Position For 2026 Runway

By Lara Goldstein

November 14, 4:23 PM

The clinical-stage psychedelics biotech GH Research PLC (NASDAQ: GHRS) reported its financial results for Q3 2023 ended September 30, showing:

GHRS

2 minute read

Enveric Biosciences’ Revenue Drops In Q3 2023 As Next-Gen Psychedelics Advance To Clinical Trials

By Lara Goldstein

November 14, 3:52 PM

Enveric Biosciences (NASDAQ: ENVB), a biopharma company developing novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, reported its financials for Q3 2023 ended September 30, 2023, showing:

ENVB